{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:26:21Z","timestamp":1786595181637,"version":"build-2736575974"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2023JH2\/101700177"],"award-info":[{"award-number":["2023JH2\/101700177"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02411-w","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T02:28:28Z","timestamp":1753496908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advances and obstacles of T cell-based immunotherapy in gynecological malignancies"],"prefix":"10.1186","volume":"24","author":[{"given":"Xi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"2411_CR1","doi-asserted-by":"publisher","unstructured":"Kordowitzki P, Lange B, Elias KM, Haigis MC, Mechsner S, Braicu IE, Sehouli J. Transforming treatment paradigms: focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin. 2025. https:\/\/doi.org\/10.3322\/caac.70008.","DOI":"10.3322\/caac.70008"},{"issue":"7","key":"2411_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1200\/JCO-24-02589","volume":"43","author":"S Gaillard","year":"2025","unstructured":"Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O\u2019Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J Clin Oncol. 2025;43(7):868\u201391.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2411_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(24)00592-8","volume":"25","author":"T May","year":"2024","unstructured":"May T. Secondary cytoreductive surgery with HIPEC: a promising therapeutic option for recurrent ovarian cancer. Lancet Oncol. 2024;25(12):1509\u201311.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2411_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2025.01.015","volume":"36","author":"LM Chambers","year":"2025","unstructured":"Chambers LM, Eskander RN, O\u2019Malley DM. Targeting the future: antibody-drug conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era. Ann Oncol. 2025;36(3):244\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"2411_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.23.01771","volume":"42","author":"J St Laurent","year":"2024","unstructured":"St Laurent J, Liu JF. Treatment approaches for platinum-resistant ovarian cancer. J Clin Oncol. 2024;42(2):127\u201333.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2411_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN. O\u2019Malley, advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9(6):851\u20139.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2411_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","volume":"33","author":"I Vergote","year":"2022","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems M, B\u00fcttner R, Lambrechts D. European experts consensus: brca\/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33(3):276\u201387.","journal-title":"Ann Oncol"},{"issue":"15","key":"2411_CR8","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","volume":"83","author":"V Garg","year":"2023","unstructured":"Garg V, Oza AM. Treatment of ovarian cancer beyond PARP inhibition: current and future options. Drugs. 2023;83(15):1365\u201385.","journal-title":"Drugs"},{"issue":"1","key":"2411_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s13046-021-02139-7","volume":"40","author":"M Tao","year":"2021","unstructured":"Tao M, Wu X. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. J Exp Clin Cancer Res. 2021;40(1):338.","journal-title":"J Exp Clin Cancer Res"},{"key":"2411_CR10","doi-asserted-by":"crossref","unstructured":"Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, Zhou D, Dong Y, Li X, Qian Y, Xu C, Tao K, Li G, Pan W, Zhong Q, Liu X, Xu S, Wang Z, Liu R, Zhang W, Shan W, Fang T, Wang S, Peng Z, Jin P, Jin N, Shi S, Chen Y, Wang M, Jiao X, Luo M, Gong W, Wang Y, Yao Y, Zhao Y, Huang X, Ji X, He Z, Zhao G, Liu R, Wu M, Chen G, Hong L, Ma D, Fang Y, Liang H, Gao Q. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187(18):4905\u201325.e24.","DOI":"10.1016\/j.cell.2024.06.013"},{"key":"2411_CR11","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.lanepe.2024.101157","volume":"49","author":"M Falcaro","year":"2025","unstructured":"Falcaro M, Castanon A, Ndlela B, Sasieni P. Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in england, 2006\u20132020: a population-based trends analysis. Lancet Reg Health Eur. 2025;49:101157.","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"2411_CR12","doi-asserted-by":"publisher","first-page":"189292","DOI":"10.1016\/j.bbcan.2025.189292","volume":"1880","author":"M Gore","year":"2025","unstructured":"Gore M, Kabekkodu SP, Chakrabarty S. Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: from mechanisms to therapeutic targets. Biochim Biophys Acta Rev Cancer. 2025;1880(2):189292.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"29","key":"2411_CR13","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1200\/JCO.23.00092","volume":"41","author":"GF Fleming","year":"2023","unstructured":"Fleming GF. Flashback foreword: concurrent chemotherapy\/radiotherapy for cervical Cancer. J Clin Oncol. 2023;41(29):4603\u20134.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2411_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","volume":"22","author":"AA Francoeur","year":"2025","unstructured":"Francoeur AA, Monk BJ, Tewari KS. Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol. 2025;22(3):182\u201399.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2411_CR15","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s11547-024-01899-4","volume":"129","author":"SE Cena","year":"2024","unstructured":"Cena SE, Olivero F, Martini S, Gianello L, Boriano A, Merlotti AM, Giannelli F, Tagliafico A, Bauckneht M, Belgioia L. External beam radiotherapy followed by image-guided adaptive brachytherapy in locally advanced cervical cancer: a multicenter retrospective analysis. Radiol Med. 2024;129(12):1906\u201315.","journal-title":"Radiol Med"},{"key":"2411_CR16","doi-asserted-by":"publisher","first-page":"1305810","DOI":"10.3389\/fimmu.2024.1305810","volume":"15","author":"YZ Wang","year":"2024","unstructured":"Wang YZ, Wang JS, Du J, Tang XL, Xiao JP. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review. Front Immunol. 2024;15:1305810.","journal-title":"Front Immunol"},{"key":"2411_CR17","doi-asserted-by":"publisher","first-page":"114057","DOI":"10.1016\/j.biopha.2022.114057","volume":"157","author":"A Awadasseid","year":"2023","unstructured":"Awadasseid A, Zhou Y, Zhang K, Tian K, Wu Y, Zhang W. Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. Biomed Pharmacother. 2023;157:114057.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2411_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41571-024-00934-7","volume":"21","author":"JA How","year":"2024","unstructured":"How JA, Jazaeri AA, Westin SN, Lawson BC, Klopp AH, Soliman PT, Lu KH. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024;21(11):781\u2013800.","journal-title":"Nat Rev Clin Oncol"},{"key":"2411_CR19","doi-asserted-by":"crossref","unstructured":"Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr., Miller A, Concin N, Powell MA, Stuart G, Bookman MA. R. participants of the Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical, Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2024;25(9):e420-e431.","DOI":"10.1016\/S1470-2045(24)00192-X"},{"issue":"2","key":"2411_CR20","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/JS9.0000000000002175","volume":"111","author":"WR Huang","year":"2025","unstructured":"Huang WR, Ou XY, Fang XZ, Tang XX, Chen L, Ling J, Song WC, Du XL. Comparing robotic, laparoscopic, and laparotomy in endometrial cancer: a network meta-analysis. Int J Surg. 2025;111(2):2208\u201315.","journal-title":"Int J Surg"},{"key":"2411_CR21","doi-asserted-by":"publisher","first-page":"e080978","DOI":"10.1136\/bmj-2024-080978","volume":"388","author":"BR Corr","year":"2025","unstructured":"Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. BMJ. 2025;388:e080978.","journal-title":"BMJ"},{"key":"2411_CR22","doi-asserted-by":"publisher","first-page":"102790","DOI":"10.1016\/j.ctrv.2024.102790","volume":"129","author":"A Salmon","year":"2024","unstructured":"Salmon A, Lebeau A, Streel S, Dheur A, Schoenen S, Goffin F, Gonne E, Kridelka F, Kakkos A, Gennigens C. Locally advanced and metastatic endometrial cancer: current and emerging therapies. Cancer Treat Rev. 2024;129:102790.","journal-title":"Cancer Treat Rev"},{"key":"2411_CR23","doi-asserted-by":"crossref","unstructured":"Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasam VS, Kim TH, Garcia J, Aguilar M, Weiser LA, Diaz Jr. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med. 2025;392(23):2297\u20132308.","DOI":"10.1056\/NEJMoa2404512"},{"issue":"4","key":"2411_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","volume":"43","author":"SL Wang","year":"2025","unstructured":"Wang SL, Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. 2025;43(4):641\u201364.","journal-title":"Cancer Cell"},{"issue":"1","key":"2411_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17(1):54.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2411_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024;24(3):213\u201327.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2411_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2411_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, Boland GM. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498\u2013512.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2411_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2024.07.723","volume":"35","author":"S Martin-Lluesma","year":"2024","unstructured":"Martin-Lluesma S, Svane IM, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Rohaan MW, Haanen J, Coukos G. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Ann Oncol. 2024;35(10):860\u201372.","journal-title":"Ann Oncol"},{"issue":"1","key":"2411_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12943-025-02294-x","volume":"24","author":"P Wawrzyniak","year":"2025","unstructured":"Wawrzyniak P, Hartman ML. Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors. Mol Cancer. 2025;24(1):89.","journal-title":"Mol Cancer"},{"issue":"1","key":"2411_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-025-01690-6","volume":"18","author":"X Zhai","year":"2025","unstructured":"Zhai X, Zhang Z, Chen Y, Wu Y, Zhen C, Liu Y, Lin Y, Chen C. Current and future therapies for small cell lung carcinoma. J Hematol Oncol. 2025;18(1):37.","journal-title":"J Hematol Oncol"},{"key":"2411_CR32","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.drup.2025.101215","volume":"81","author":"S Dong","year":"2025","unstructured":"Dong S, Li X, Huang Q, Li Y, Li J, Zhu X, Xue C, Chen R, Zeng Y, Wu J, Zhong Y, Hu S. Resistance to immunotherapy in non-small cell lung cancer: unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resist Updat. 2025;81:101215.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"2411_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","volume":"31","author":"R Dummer","year":"2025","unstructured":"Dummer R, Robert C, Scolyer RA, Taube JM, Tetzlaff MT, Menzies AM, Hill A, Grob JJ, Portnoy DC, Lebbe C, Khattak MA, Cohen J, Bar-Sela G, Mehmi I, Shapira-Frommer R, Meyer N, Webber AL, Ren Y, Fukunaga-Kalabis M, Krepler C. Long, neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1\/2 trial. Nat Med. 2025;31(1):144\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"2411_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu J, Wang X, Li Z, Gao S, Mao L, Dai J, Li C, Cui C, Chi Z, Sheng X, Lai Y, Tan Z, Lian B, Tang B, Yan X, Li S, Zhou L, Wei X, Li J, Guo J, Si L. Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial. Signal Transduct Target Ther. 2024;9(1):318.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2411_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cmet.2024.12.013","volume":"37","author":"X Zhu","year":"2025","unstructured":"Zhu X, Hu M, Huang X, Li L, Lin X, Shao X, Li J, Du X, Zhang X, Sun R, Tong T, Ma Y, Ning L, Jiang Y, Zhang Y, Shao Y, Wang Z, Zhou Y, Ding J, Zhao Y, Xuan B, Zhang H, Zhang Y, Hong J, Fang JY, Xiao X, Shen B, He S, Chen H. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab. 2025;37(4):806\u201323. e6.","journal-title":"Cell Metab"},{"issue":"9","key":"2411_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41(9):1551\u201366.","journal-title":"Cancer Cell"},{"issue":"12","key":"2411_CR37","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41590-024-02015-4","volume":"25","author":"S Goswami","year":"2024","unstructured":"Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024;25(12):2186\u201399.","journal-title":"Nat Immunol"},{"issue":"8","key":"2411_CR38","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"2411_CR39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379.","journal-title":"Cancer Cell"},{"key":"2411_CR40","doi-asserted-by":"crossref","unstructured":"Abken H. CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges. Nat Rev Gastroenterol Hepatol. 2025;22(7):463\u201380.","DOI":"10.1038\/s41575-025-01062-y"},{"issue":"1","key":"2411_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22(1):141.","journal-title":"Mol Cancer"},{"issue":"1","key":"2411_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","volume":"41","author":"SM Norberg","year":"2023","unstructured":"Norberg SM, Hinrichs CS. Engineered T cell therapy for viral and non-viral epithelial cancers. Cancer Cell. 2023;41(1):58\u201369.","journal-title":"Cancer Cell"},{"key":"2411_CR43","doi-asserted-by":"crossref","unstructured":"Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025;22(3):163\u201381.","DOI":"10.1038\/s41571-024-00984-x"},{"issue":"8","key":"2411_CR44","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","volume":"42","author":"AA Sarnaik","year":"2024","unstructured":"Sarnaik AA, Hwu P, Mule JJ, Pilon-Thomas S. Tumor-infiltrating lymphocytes: a new hope. Cancer Cell. 2024;42(8):1315\u20138.","journal-title":"Cancer Cell"},{"issue":"22","key":"2411_CR45","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. Cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"8","key":"2411_CR46","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325.","journal-title":"Cancer Cell"},{"key":"2411_CR47","doi-asserted-by":"crossref","unstructured":"Ouladan S, Orouji E. Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy. J Clin Oncol. 2025;43(8):994\u20131005.","DOI":"10.1200\/JCO-24-02081"},{"issue":"4","key":"2411_CR48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506\u201315.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"2411_CR49","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, Neeser A, Pires IS, Yousefpour P, Gregory J, Qureshi K, Dye J, Abraham W, Suh H, Li N, Love JC, Irvine DJ. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148\u2013e316520.","journal-title":"Cell"},{"issue":"4","key":"2411_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Riviere I, Sadelain M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13(4):829\u201343.","journal-title":"Cancer Discov"},{"issue":"1","key":"2411_CR51","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","volume":"15","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto G, McIntyre B, Hines MG, Giudice AM, Garcia-Gerique L, Hoffmann J, Mishra P, Matlaga S, Lombardi S, Shraim R, Schurch PM, Yarmarkovich M, Hofmann TJ, Alikarami F, Martinez D, Tsang M, Gil-de-Gomez L, Spear TT, Bernt KM, Wolpaw AJ, Dimitrov DS, Li W, Bosse KR. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nat Commun. 2024;15(1):7141.","journal-title":"Nat Commun"},{"key":"2411_CR52","first-page":"377","volume":"33","author":"C Zhu","year":"2024","unstructured":"Zhu C, Wu Q, Sheng T, Shi J, Shen X, Yu J, Du Y, Sun J, Liang T, He K, Ding Y, Li H, Gu Z, Wang W. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. Bioact Mater. 2024;33:377\u201395.","journal-title":"Bioact Mater"},{"issue":"1","key":"2411_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12951-024-03005-2","volume":"22","author":"Y Feng","year":"2024","unstructured":"Feng Y, Tang Q, Wang B, Yang Q, Zhang Y, Lei L, Li S. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnol. 2024;22(1):737.","journal-title":"J Nanobiotechnol"},{"issue":"6576","key":"2411_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tombacz I, Yadegari A, Mendez Fernandez PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Pure E, June CH, Aghajanian H, Weissman D, Parhiz H, Epstein JA. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.","journal-title":"Science"},{"issue":"1","key":"2411_CR55","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liousia M, Assenmacher CA, June CH, Albelda SM, Pure E. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14(1):5110.","journal-title":"Nat Commun"},{"key":"2411_CR56","doi-asserted-by":"crossref","unstructured":"Anderson KG, Braun DA, Buque A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. J Immunother Cancer. 2023;11(6).","DOI":"10.1136\/jitc-2022-006533"},{"issue":"1","key":"2411_CR57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12943-024-01981-5","volume":"23","author":"Q Dang","year":"2024","unstructured":"Dang Q, Li B, Jin B, Ye Z, Lou X, Wang T, Wang Y, Pan X, Hu Q, Li Z, Ji S, Zhou C, Yu X, Qin Y, Xu X. Cancer immunometabolism: advent, challenges, and perspective. Mol Cancer. 2024;23(1):72.","journal-title":"Mol Cancer"},{"issue":"10","key":"2411_CR58","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205.","journal-title":"Immunity"},{"issue":"10","key":"2411_CR59","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM, Wherry EJ. CD8(+) T cells in the cancer-immunity cycle. Immunity. 2023;56(10):2231\u201353.","journal-title":"Immunity"},{"issue":"10","key":"2411_CR60","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56(10):2218\u201330.","journal-title":"Immunity"},{"issue":"11","key":"2411_CR61","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","volume":"42","author":"LF Somarribas Patterson","year":"2021","unstructured":"Somarribas Patterson LF, Vardhana SA. Metabolic regulation of the cancer-immunity cycle. Trends Immunol. 2021;42(11):975\u201393.","journal-title":"Trends Immunol"},{"issue":"1","key":"2411_CR62","doi-asserted-by":"publisher","first-page":"e2401927","DOI":"10.1002\/adhm.202401927","volume":"14","author":"Y Lee","year":"2025","unstructured":"Lee Y, Min J, Kim S, Park W, Ko J, Jeon NL. Recapitulating the cancer-immunity cycle on a chip. Adv Healthc Mater. 2025;14(1):e2401927.","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"2411_CR63","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cac2.12587","volume":"44","author":"W Sun","year":"2024","unstructured":"Sun W, Hu S, Wang X. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies. Cancer Commun (Lond). 2024;44(9):1071\u201397.","journal-title":"Cancer Commun (Lond)"},{"key":"2411_CR64","doi-asserted-by":"publisher","first-page":"115306","DOI":"10.1016\/j.addr.2024.115306","volume":"209","author":"Y Choi","year":"2024","unstructured":"Choi Y, Seok SH, Yoon HY, Ryu JH, Kwon IC. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade. Adv Drug Deliv Rev. 2024;209:115306.","journal-title":"Adv Drug Deliv Rev"},{"issue":"24","key":"2411_CR65","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-23-3296","volume":"30","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Wucherpfennig KW, Tissue-Resident T. Cells in clinical response and immune-related adverse events of immune checkpoint blockade. Clin Cancer Res. 2024;30(24):5527\u201334.","journal-title":"Clin Cancer Res"},{"key":"2411_CR66","doi-asserted-by":"crossref","unstructured":"Moore J, Gkantalis J, Guix I, Chou W, Yuen K, Lazar AA, Spitzer M, Combes A, Barcellos-Hoff MH. Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade. J Immunother Cancer. 2025;13(3).","DOI":"10.1136\/jitc-2024-010528"},{"key":"2411_CR67","doi-asserted-by":"crossref","unstructured":"Xiong G, Chen Z, Liu Q, Peng F, Zhang C, Cheng M, Ling R, Chen S, Liang Y, Chen D, Zhou Q. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs. J Immunother Cancer. 2024;12(5).","DOI":"10.1136\/jitc-2023-008662"},{"issue":"1","key":"2411_CR68","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-025-02253-6","volume":"24","author":"L Zhang","year":"2025","unstructured":"Zhang L, Lin Y, Hu L, Wang Y, Hu C, Shangguan X, Tang S, Chen J, Hu P, Chen ZS, Ke ZF, Chen Z. Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis. Mol Cancer. 2025;24(1):119.","journal-title":"Mol Cancer"},{"key":"2411_CR69","doi-asserted-by":"publisher","unstructured":"Zhang C, Wu P, Li D, Zhou J, Lin C, Gu X, Shang D, Ma R, Liu J, Zhang G, Wang P, Che Y, Zeng Q, Peng J, Zhao B, Sun N, He J. Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: a comprehensive reanalysis of randomized controlled trials. Med. 2025:100669. https:\/\/doi.org\/10.1016\/j.medj.2025.100669. Online ahead of print.","DOI":"10.1016\/j.medj.2025.100669"},{"issue":"9","key":"2411_CR70","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","volume":"42","author":"K Wang","year":"2024","unstructured":"Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells. Cancer Cell. 2024;42(9):1582\u2013e159710.","journal-title":"Cancer Cell"},{"issue":"5","key":"2411_CR71","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ccell.2024.03.001","volume":"42","author":"G Xue","year":"2024","unstructured":"Xue G, Li X, Kalim M, Fang J, Jiang Z, Zheng N, Wang Z, Li X, Abdelrahim M, He Z, Nikiforov M, Jin G, Lu Y. Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer Cell. 2024;42(5):780\u2013e7966.","journal-title":"Cancer Cell"},{"issue":"12","key":"2411_CR72","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/neuonc\/noae177","volume":"26","author":"J Duerinck","year":"2024","unstructured":"Duerinck J, Lescrauwaet L, Dirven I, Del\u2019haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B. Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. Neuro Oncol. 2024;26(12):2208\u201321.","journal-title":"Neuro Oncol"},{"key":"2411_CR73","doi-asserted-by":"crossref","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Muniz L, Koch A, Janssens A, Alexandru S, Bohnet FV, Moiseyenko Y, Gao Y, Watanabe C, Coronado Erdmann P, Sathyanarayana S, Meadows-Shropshire SI, Blum MP, Pulla TI, CheckMate. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756\u20131769.","DOI":"10.1056\/NEJMoa2311926"},{"key":"2411_CR74","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"3896","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, Bernabe R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, Lopez Vivanco G, Camps C, Lopez-Castro R, Moran T, Barneto I, Rodriguez-Abreu D, Serna-Blasco R, Benitez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martin-Lopez J, Cruz-Bermudez A, Massuti B, Romero A. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;3896:504\u201313.","journal-title":"N Engl J Med"},{"issue":"10481","key":"2411_CR75","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, Zhong H, Li J, Cheng Y, Sun Y, Ge H, Yao J, Shi Q, Zhou M, Chen B, Han Z, Wang J, Bu Q, Zhao Y, Chen J, Nie L, Li G, Li X, Yu X, Ji Y, Sun D, Ai X, Chu Q, Lin Y, Hao J, Huang D, Zhou C, Shan J, Yang H, Liu X, Wang J, Shang Y, Mei X, Yang J, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhou C. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 2025;405(10481):839\u201349.","journal-title":"Lancet"},{"issue":"10459","key":"2411_CR76","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S. Investigators, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240\u201352.","journal-title":"Lancet"},{"issue":"10336","key":"2411_CR77","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz L, Merino MA, Khattak D, Schadendorf GV, Long PA, Ascierto M, Mandala F, De Galitiis A, Haydon R, Dummer JJ, Grob C, Robert MS, Carlino P, Mohr A, Poklepovic VK, Sondak RA, Scolyer JM, Kirkwood K, Chen SJ, Diede S, Ahsan N, Ibrahim AMM, Eggermont K-. Investigators, pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718\u201329.","journal-title":"Lancet"},{"key":"2411_CR78","doi-asserted-by":"crossref","unstructured":"Patel SP, Othus M, Chen Y, Wright GP Jr., Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813\u2013823.","DOI":"10.1056\/NEJMoa2211437"},{"issue":"5","key":"2411_CR79","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/JCO.24.00646","volume":"43","author":"PL Swiecicki","year":"2025","unstructured":"Swiecicki PL, Yilmaz E, Rosenberg AJ, Fujisawa T, Bruce JY, Meng C, Wozniak M, Zhao Y, Mihm M, Kaplan J, Gorla S, Geiger JL. Phase II trial of enfortumab vedotin in patients with previously treated advanced head and neck cancer. J Clin Oncol. 2025;43(5):578\u201388.","journal-title":"J Clin Oncol"},{"key":"2411_CR80","doi-asserted-by":"crossref","unstructured":"Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G, Jr. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial. J Clin Oncol. 2024;42(25):2989\u20132999.","DOI":"10.1200\/JCO.23.02625"},{"issue":"1","key":"2411_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"2411_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal R, Valderrama BP, Bellmunt J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol. 2024;21(1):8\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2411_CR83","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","volume":"21","author":"E Ghisoni","year":"2024","unstructured":"Ghisoni E, Morotti M, Sarivalasis A, Grimm AJ, Kandalaft L, Laniti DD, Coukos G. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nat Rev Clin Oncol. 2024;21(11):801\u201317.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2411_CR84","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41591-024-02942-7","volume":"30","author":"CF Friedman","year":"2024","unstructured":"Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr., Mueller JJ, Makker V, Tew WP, O\u2019Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat Med. 2024;30(5):1330\u20138.","journal-title":"Nat Med"},{"issue":"13","key":"2411_CR85","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.23.02479","volume":"42","author":"PH Luo","year":"2024","unstructured":"Luo PH, Mo DC, Wang HL, Liang XJ, Huang JF. Predicted value of PD-L1 for patients with cervical Cancer treated with pembrolizumab. J Clin Oncol. 2024;42(13):1596.","journal-title":"J Clin Oncol"},{"key":"2411_CR86","doi-asserted-by":"crossref","unstructured":"Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Ya\u00f1ez E, G\u00fcm\u00fc\u015f M, Samou\u00eblian M, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D. First-line Pembrolizumab\u2009+\u2009Chemotherapy versus Placebo\u2009+\u2009Chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505\u20135511.","DOI":"10.1200\/JCO.23.00914"},{"issue":"12","key":"2411_CR87","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1056\/NEJMc2501311","volume":"392","author":"A Santhosh","year":"2025","unstructured":"Santhosh A. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(12):1245\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"2411_CR88","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Sandhu S, Lebbe C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J, CheckMate I. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"2411_CR89","doi-asserted-by":"crossref","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen J, Ch\u2019ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grunhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbe C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel F, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den MAM, Boer V, Atkinson M, Khattak MC, Andrews AJM, van den Eertwegh MJ, Boers-Sonderen GAP, Hospers MS, Carlino JB, de Groot E, Kapiteijn KPM, Suijkerbuijk P, Rutkowski S, Sandhu, A.A.M., van der Veldt GV. Long, neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696\u20131708.","DOI":"10.1056\/NEJMoa2402604"},{"key":"2411_CR90","volume-title":"Interdisciplinary renal cell carcinoma working group of the, prospective randomised Phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal","author":"L Bergmann","year":"2025","unstructured":"Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Flechon A, Grimm MO, Bedke J, Barthelemy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Florcken A, Suarez C, Maroto P, Grunwald V, Oosting SF, Kopecky J, Zschabitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB DKG. Interdisciplinary renal cell carcinoma working group of the, prospective randomised phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal. Ann Oncol: Cell Cancer - Results of the SUNNIFORECAST Trial. 2025."},{"issue":"11","key":"2411_CR91","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barth\u00e9l\u00e9my P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Gr\u00fcnwald V, Rini BI, Jiang R, Desilva H, Fedorov V, Lee CW, Motzer RJ. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III checkmate 214 trial. Ann Oncol. 2024;35(11):1026\u201338.","journal-title":"Ann Oncol"},{"issue":"10460","key":"2411_CR92","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejia F, Helpman L, Akilli H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR. -c.G.-K.-A. Investigators, pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10460):1321\u201332.","journal-title":"Lancet"},{"key":"2411_CR93","doi-asserted-by":"crossref","unstructured":"Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Ya\u00f1ez E, G\u00fcm\u00fc\u015f M, Samou\u00eblian M, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856\u20131867.","DOI":"10.1056\/NEJMoa2112435"},{"issue":"31","key":"2411_CR94","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.19.00739","volume":"37","author":"RW Naumann","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, Lopez-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II checkmate 358 trial. J Clin Oncol. 2019;37(31):2825\u201334.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2411_CR95","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1470-2045(24)00088-3","volume":"25","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Moore K, Meyer T, Lopez-Picazo Gonzalez J, Devriese LA, Amin A, Lao CD, Boni V, Sharfman WH, Park JC, Tahara M, Topalian SL, Magallanes M, Molina Alavez A, Khan TA, Copigneaux C, Lee M, Garnett-Benson C, Wang X, Naumann RW. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1\u20132, open-label, multicohort trial. Lancet Oncol. 2024;25(5):588\u2013602.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2411_CR96","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, Gonzalez-Martin A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"2411_CR97","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","volume":"11","author":"R Kristeleit","year":"2025","unstructured":"Kristeleit R, Devlin MJ, Clamp A, Gourley C, Roux R, Hall M, Nirsimloo R, Kounnis V, Sage L, Narayanan P, Herrington CS, Arora R, Farrelly L, Hughes L, Counsell N, Miller RE. Pembrolizumab in patients with advanced clear cell gynecological cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2025;11(4):377\u201385.","journal-title":"JAMA Oncol"},{"issue":"26","key":"2411_CR98","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"2411_CR99","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S1470-2045(24)00437-6","volume":"25","author":"Z Peng","year":"2024","unstructured":"Peng Z, Li H, Gao Y, Sun L, Jiang J, Xia B, Huang Y, Zhang Y, Xia Y, Zhang Y, Shen Y, Huang B, Nie J, Chen X, Liu X, Feng C, Li Z, Zhang W, Tao K, Zhang Q, Duan S, Chen Y, Chen Y, Wang W, Zheng H, Lu Y, Liu Y, Wang L, Qi W, He Y, Tian Y, Group NPR, Li G, Ma D, Gao Q. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(10):1288\u201397.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2411_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","volume":"36","author":"P Harter","year":"2025","unstructured":"Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alia EM, Matsumoto T, Vergote I, Colombo N, Maenpaa J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Perez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I PA-E-o. Investigators, efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line Olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2025;36(2):185\u201396.","journal-title":"Ann Oncol"},{"issue":"2","key":"2411_CR101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(24)00674-0","volume":"26","author":"AM Oza","year":"2025","unstructured":"Oza AM, Lisyanskaya A, Fedenko A, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Poka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Kristeleit R. Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2025;26(2):249\u201364.","journal-title":"Lancet Oncol"},{"key":"2411_CR102","doi-asserted-by":"crossref","unstructured":"Martin-Lluesma S, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Villacampa G, Galvao V, Lostes J, Munoz-Couselo E, Rotxes M, Villalobos X, Munoz S, Haanen J, Svane IM, Piulats JM, Martin-Liberal J, Gros A, Coukos G, Garralda E. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2025;36(8):909\u201319.","DOI":"10.1016\/j.annonc.2025.04.001"},{"issue":"1","key":"2411_CR103","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1124\/pharmrev.124.001070","volume":"77","author":"MB Ward","year":"2025","unstructured":"Ward MB, Jones AB, Krenciute G. Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies. Pharmacol Rev. 2025;77(1):100011.","journal-title":"Pharmacol Rev"},{"key":"2411_CR104","doi-asserted-by":"publisher","first-page":"102715","DOI":"10.1016\/j.arr.2025.102715","volume":"107","author":"S Qi","year":"2025","unstructured":"Qi S, Li J, Gu X, Zhang Y, Zhou W, Wang F, Wang W. Impacts of ageing on the efficacy of CAR-T cell therapy. Ageing Res Rev. 2025;107:102715.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"2411_CR105","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Han J, Wang D, Cai M, Xu Y, Hu Y, Chen H, He W, Zhang J. Anti-PD-1 antibody armored \u03b3\u03b4 T cells enhance anti-tumor efficacy in ovarian cancer. Signal Transduct Target Ther. 2023;8(1):399.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2411_CR106","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41418-023-01229-7","volume":"30","author":"T Mondal","year":"2023","unstructured":"Mondal T, Gaur H, Wamba BEN, Michalak AG, Stout C, Watson MR, Aleixo SL, Singh A, Condello S, Faller R, Leiserowitz GS, Bhatnagar S, Tushir-Singh. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death Differ. 2023;30(11):2408\u201331.","journal-title":"Cell Death Differ"},{"issue":"11","key":"2411_CR107","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","volume":"81","author":"E Schoutrop","year":"2021","unstructured":"Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I, Mattsson J. Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res. 2021;81(11):3022\u201335.","journal-title":"Cancer Res"},{"key":"2411_CR108","doi-asserted-by":"crossref","unstructured":"Moravec Z, Haanen J, Schumacher TN, Scheper W. Learning the language of T cell receptors through large-scale screening. Cancer Cell. 2025;43(6):993\u20137.","DOI":"10.1016\/j.ccell.2025.03.032"},{"issue":"790","key":"2411_CR109","doi-asserted-by":"publisher","first-page":"eadr8941","DOI":"10.1126\/scitranslmed.adr8941","volume":"17","author":"R Porret","year":"2025","unstructured":"Porret R, Alcaraz-Serna A, Peter B, Bernier-Latmani J, Cecchin R, Alfageme-Abello O, Ermellino L, Hafezi M, Pace E, du Pre MF, Lana E, Golshayan D, Velin D, Eyquem J, Tang Q, Petrova TV, Coukos G, Irving M, Pot C, Pantaleo G, Sollid LM, Muller YD. T cell receptor precision editing of regulatory T cells for celiac disease. Sci Transl Med. 2025;17(790):eadr8941.","journal-title":"Sci Transl Med"},{"issue":"790","key":"2411_CR110","doi-asserted-by":"publisher","first-page":"eadp0675","DOI":"10.1126\/scitranslmed.adp0675","volume":"17","author":"I Raphael","year":"2025","unstructured":"Raphael I, Xiong Z, Sneiderman CT, Raphael RA, Mash M, Schwegman L, Jackson SA, O\u2019Brien C, Anderson KJ, Sever RE, Hendrikse LD, Vincze SR, Diaz A, Felker J, Nazarian J, Nechemia-Arbely Y, Hu B, Kammula US, Agnihotri S, Rich JN, Broniscer A, Drappatz J, Abel TJ, Uttam S, Hwang EI, Pearce TM, Taylor MD, Nisnboym M, Forsthuber TG, Pollack IF, Chikina M, Rajasundaram D, Kohanbash G. The T cell receptor landscape of childhood brain tumors. Sci Transl Med. 2025;17(790):eadp0675.","journal-title":"Sci Transl Med"},{"issue":"9","key":"2411_CR111","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S1470-2045(19)30541-8","volume":"20","author":"TK Burki","year":"2019","unstructured":"Burki TK. TCR gene therapy for HPV-associated epithelial cancers. Lancet Oncol. 2019;20(9):e474.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2411_CR112","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1158\/0008-5472.CAN-09-4299","volume":"70","author":"PJ de Vos","year":"2010","unstructured":"de Vos PJ, van Steenwijk M, Heusinkveld TH, Ramwadhdoebe MJ, Lowik JM, van der Hulst R, Goedemans SJ, Piersma GG, Kenter SH, van der Burg. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 2010;70(7):2707\u201317.","journal-title":"Cancer Res"},{"issue":"4","key":"2411_CR113","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","volume":"25","author":"C Luri-Rey","year":"2025","unstructured":"Luri-Rey C, Teijeira A, Wculek SK, de Andrea C, Herrero C, Lopez-Janeiro A, Rodriguez-Ruiz ME, Heras I, Aggelakopoulou M, Berraondo P, Sancho D, Melero I. Cross-priming in cancer immunology and immunotherapy. Nat Rev Cancer. 2025;25(4):249\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2411_CR114","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","volume":"10","author":"F Guan","year":"2025","unstructured":"Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y, Liu Z, Xia Z, Zhang H, Cheng Q. Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther. 2025;10(1):93.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2411_CR115","doi-asserted-by":"publisher","first-page":"e1026529","DOI":"10.1080\/2162402X.2015.1026529","volume":"4","author":"NL Berinstein","year":"2015","unstructured":"Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015;4(8):e1026529.","journal-title":"Oncoimmunology"},{"issue":"12","key":"2411_CR116","doi-asserted-by":"publisher","first-page":"e1665460","DOI":"10.1080\/2162402X.2019.1665460","volume":"8","author":"HL MacGregor","year":"2019","unstructured":"MacGregor HL, Garcia-Batres C, Sayad A, Elia A, Berman HK, Toker A, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, Nguyen LT, Ohashi PS. Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating apcs and higher CXCL17 expression in human epithelial ovarian cancer. Oncoimmunology. 2019;8(12):e1665460.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2411_CR117","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1186\/s12967-024-05846-9","volume":"22","author":"LK Berry","year":"2024","unstructured":"Berry LK, Pullikuth AK, Stearns KL, Wang Y, Wagner CJ, Chou JW, Darby JP, Kelly MG, Mall R, Leung M, Chifman J, Miller LD. A patient stratification signature mirrors the immunogenic potential of high grade serous ovarian cancers. J Transl Med. 2024;22(1):1048.","journal-title":"J Transl Med"},{"issue":"4","key":"2411_CR118","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41590-025-02113-x","volume":"26","author":"A Jay","year":"2025","unstructured":"Jay A, Pondevida CM, Vahedi G. The epigenetic landscape of fate decisions in T cells. Nat Immunol. 2025;26(4):544\u201356.","journal-title":"Nat Immunol"},{"key":"2411_CR119","doi-asserted-by":"crossref","unstructured":"Ma K, Xu Y, Cheng H, Tang K, Ma J, Huang B. T cell-based cancer immunotherapy: opportunities and challenges. Sci Bull (Beijing). 2025;70(11):1872\u201390.","DOI":"10.1016\/j.scib.2025.03.054"},{"issue":"7","key":"2411_CR120","doi-asserted-by":"publisher","first-page":"1903301","DOI":"10.1002\/advs.201903301","volume":"7","author":"S Cheng","year":"2020","unstructured":"Cheng S, Xu C, Jin Y, Li Y, Zhong C, Ma J, Yang J, Zhang N, Li Y, Wang C, Yang Z, Wang Y. Artificial mini dendritic cells boost T cell-based immunotherapy for ovarian cancer. Adv Sci (Weinh). 2020;7(7):1903301.","journal-title":"Adv Sci (Weinh)"},{"key":"2411_CR121","doi-asserted-by":"crossref","unstructured":"Sima LE, Chen S, Cardenas H, Zhao G, Wang Y, Ivan C, Huang H, Zhang B, Matei D. Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1\/STAT3 phosphorylation in ovarian cancer. J Immunother Cancer. 2021;9(9).","DOI":"10.1136\/jitc-2021-002682"},{"key":"2411_CR122","doi-asserted-by":"crossref","unstructured":"Anderson KG, Oda SK, Bates BM, Burnett MG, Rodgers Suarez M, Ruskin SL, Greenberg PD. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. J Immunother Cancer. 2022;10(3).","DOI":"10.1136\/jitc-2021-003959"},{"issue":"2","key":"2411_CR123","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","volume":"10","author":"AJ Anandappa","year":"2020","unstructured":"Anandappa AJ, Wu CJ, Ott PA. Directing traffic: how to effectively drive T cells into tumors. Cancer Discov. 2020;10(2):185\u201397.","journal-title":"Cancer Discov"},{"issue":"1","key":"2411_CR124","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noy084","volume":"21","author":"NM Ratnam","year":"2019","unstructured":"Ratnam NM, Gilbert MR, Giles AJ. Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro Oncol. 2019;21(1):37\u201346.","journal-title":"Neuro Oncol"},{"issue":"4","key":"2411_CR125","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1078-0432.CCR-16-1433","volume":"23","author":"CS Lo","year":"2017","unstructured":"Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, Rahimi K, Shaw PA, Clarke BA, Nelson BH. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925\u201334.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2411_CR126","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","volume":"120","author":"K Mulati","year":"2019","unstructured":"Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, Taki M, Budiman K, Zeng X, Hosoe Y, Azuma M, Konishi I, Mandai M. VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 2019;120(1):115\u201327.","journal-title":"Br J Cancer"},{"key":"2411_CR127","doi-asserted-by":"publisher","first-page":"768115","DOI":"10.3389\/fimmu.2021.768115","volume":"12","author":"L Yu","year":"2021","unstructured":"Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J. Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer. Front Immunol. 2021;12:768115.","journal-title":"Front Immunol"},{"issue":"9","key":"2411_CR128","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/2326-6066.CIR-19-0258","volume":"7","author":"KG Anderson","year":"2019","unstructured":"Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD. Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced-stage ovarian cancer. Cancer Immunol Res. 2019;7(9):1412\u201325.","journal-title":"Cancer Immunol Res"},{"key":"2411_CR129","doi-asserted-by":"crossref","unstructured":"McGray AJR, Chiello JL, Tsuji T, Long M, Maraszek K, Gaulin N, Rosario SR, Hess SM, Abrams SI, Kozbor D, Odunsi K, Zsiros E. BiTE secretion by adoptively transferred stem-like T cells improves FR\u03b1\u2009+\u2009ovarian cancer control. J Immunother Cancer. 2023;11(6).","DOI":"10.1136\/jitc-2023-006863"},{"issue":"7","key":"2411_CR130","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41388-023-02918-w","volume":"43","author":"CJ Wu","year":"2024","unstructured":"Wu CJ, Pan KF, Chen JQ, Tao Y, Liu YC, Chen BR, Hsu C, Wang MY, Sheu BC, Hsiao M, Hua KT, Wei LH. Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment. Oncogene. 2024;43(7):511\u201323.","journal-title":"Oncogene"},{"issue":"9","key":"2411_CR131","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1016\/j.ymthe.2024.06.029","volume":"32","author":"S Basnet","year":"2024","unstructured":"Basnet S, Van der Heijden M, Quixabeira DCA, Jirovec E, Gr\u00f6nberg-V\u00e4h\u00e4-Koskela SAM, Clubb JHA, Kanerva A, Pakola S, Haybout L, Arias V, Hemminki O, Kudling T, Zafar S, Cervera-Carrascon V, Santos JM, Hemminki A. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine. Mol Ther. 2024;32(9):3114\u201327.","journal-title":"Mol Ther"},{"key":"2411_CR132","doi-asserted-by":"crossref","unstructured":"Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K, Yoshimoto M, Miura-Okuda M, Uchikawa R, Kato C, Shinozuka J, Akai S, Naoi S, Tomioka N, Nagaya N, Pang CL, Garvita G, Feng S, Shimada M, Kamata-Sakurai M, Aburatani H, Kitazawa T, Igawa T. SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3\/CD137. J Immunother Cancer. 2024;12(10).","DOI":"10.1136\/jitc-2024-009563"},{"key":"2411_CR133","doi-asserted-by":"crossref","unstructured":"Zhong Y, Wang Y, Wang C, Cao K, Wang X, Xu X, Yang M, Zhang G, Liu H, Lu J. Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer. J Immunother Cancer. 2025;13(2).","DOI":"10.1136\/jitc-2024-011230"},{"issue":"1","key":"2411_CR134","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41598-024-51217-1","volume":"14","author":"KJC Galpin","year":"2024","unstructured":"Galpin KJC, Rodriguez GM, Maranda V, Cook DP, Macdonald E, Murshed H, Zhao S, McCloskey CW, Chruscinski A, Levy GA, Ardolino M, Vanderhyden BC. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models. Sci Rep. 2024;14(1):787.","journal-title":"Sci Rep"},{"key":"2411_CR135","doi-asserted-by":"crossref","unstructured":"Park J, Kim JC, Lee YJ, Kim S, Kim SW, Shin EC, Lee JY, Park SH. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8(+) TILs based on BRCA1\/2 mutation status in epithelial ovarian cancers. J Immunother Cancer. 2024;12(7).","DOI":"10.1136\/jitc-2024-009058"},{"issue":"1","key":"2411_CR136","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","volume":"23","author":"S Peng","year":"2024","unstructured":"Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, Luo P, Bai Y. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol Cancer. 2024;23(1):58.","journal-title":"Mol Cancer"},{"issue":"7","key":"2411_CR137","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.trecan.2024.03.010","volume":"10","author":"H Shi","year":"2024","unstructured":"Shi H, Chen S, Chi H. Immunometabolism of CD8(+) T cell differentiation in cancer. Trends Cancer. 2024;10(7):610\u201326.","journal-title":"Trends Cancer"},{"key":"2411_CR138","doi-asserted-by":"publisher","first-page":"216805","DOI":"10.1016\/j.canlet.2024.216805","volume":"588","author":"V Kannen","year":"2024","unstructured":"Kannen V, Grant DM, Matthews J. The mast cell-T lymphocyte axis impacts cancer: friend or foe? Cancer Lett. 2024;588:216805.","journal-title":"Cancer Lett"},{"key":"2411_CR139","doi-asserted-by":"crossref","unstructured":"Jin BY, Campbell TE, Draper LM, Stevanovi\u0107 S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3(8).","DOI":"10.1172\/jci.insight.99488"},{"issue":"1","key":"2411_CR140","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41467-019-09263-1","volume":"10","author":"Y Cao","year":"2019","unstructured":"Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC. ER stress-induced mediator C\/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nat Commun. 2019;10(1):1280.","journal-title":"Nat Commun"},{"key":"2411_CR141","doi-asserted-by":"crossref","unstructured":"Santos JM, Heini\u00f6 C, Cervera-Carrascon V, Quixabeira DCA, Siurala M, Havunen R, Butzow R, Zafar S, de Gruijl T, Lassus H, Kanerva A, Hemminki A. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2019-000188"},{"issue":"1","key":"2411_CR142","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu L, Wang A, Liu X, Han S, Sun Y, Zhang J, Guo L, Zhang Y. Blocking TIGIT\/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer. J Transl Med. 2022;20(1):280.","journal-title":"J Transl Med"},{"issue":"1","key":"2411_CR143","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12967-023-04271-8","volume":"21","author":"H Zhao","year":"2023","unstructured":"Zhao H, Wu L, Dai J, Sun K, Zi Z, Guan J, Zhang L. Ligand-based adoptive T cell targeting CA125 in ovarian cancer. J Transl Med. 2023;21(1):596.","journal-title":"J Transl Med"},{"key":"2411_CR144","doi-asserted-by":"crossref","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: the evolution of CAR-T cell therapy. Mol Ther. 2025;33(5):2123\u201340.","DOI":"10.1016\/j.ymthe.2025.03.005"},{"key":"2411_CR145","doi-asserted-by":"crossref","unstructured":"Lee MJ, Cichocki F, Miller JS. Chimeric antigen receptor therapies: Development, design, and implementation. J Allergy Clin Immunol. 2025;156(1):70\u201380.","DOI":"10.1016\/j.jaci.2025.04.005"},{"key":"2411_CR146","doi-asserted-by":"crossref","unstructured":"Braun T, Kuschel F, Reiche K, Merz M, Herling M. Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia. 2025;39(6):1337\u201341.","DOI":"10.1038\/s41375-025-02574-x"},{"key":"2411_CR147","doi-asserted-by":"crossref","unstructured":"Khalifeh M, Hopewell E, Salman H. CAR T cell therapy for treatment of acute myeloid leukemia, advances and outcomes. Mol Ther. 2025;33(6):2441\u201353.","DOI":"10.1016\/j.ymthe.2025.03.052"},{"key":"2411_CR148","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru M, O\u2019Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;13:102.","journal-title":"J Transl Med"},{"issue":"3","key":"2411_CR149","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CJI.0000000000000160","volume":"40","author":"JL Tanyi","year":"2017","unstructured":"Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH. Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells. J Immunother. 2017;40(3):104\u20137.","journal-title":"J Immunother"},{"issue":"2","key":"2411_CR150","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00262-022-03238-w","volume":"72","author":"J Chen","year":"2023","unstructured":"Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, Shi R, Ma L, Jia S, Zhang Y, Zhang Q, Liang J, Yao S, Hu Z, Guo Z. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72(2):409\u201325.","journal-title":"Cancer Immunol Immunother"},{"key":"2411_CR151","doi-asserted-by":"crossref","unstructured":"Daigre J, Martinez-Osuna M, Bethke M, Steiner L, Dittmer V, Krischer K, Bleilevens C, Brauner J, Kopatz J, Grundmann MD, Praveen P, Eckardt D, Bosio A, Herbel C. Preclinical evaluation of novel folate receptor 1-directed CAR T cells for ovarian cancer. Cancers (Basel). 2024;16(2).","DOI":"10.3390\/cancers16020333"},{"key":"2411_CR152","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","volume":"20","author":"R Shu","year":"2021","unstructured":"Shu R, Evtimov VJ, Hammett MV, Nguyen NN, Zhuang J, Hudson PJ, Howard MC, Pupovac A, Trounson AO, Boyd RL. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. Mol Ther Oncolytics. 2021;20:325\u201341.","journal-title":"Mol Ther Oncolytics"},{"issue":"Pt 3","key":"2411_CR153","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semcancer.2022.02.008","volume":"86","author":"N Kumar","year":"2022","unstructured":"Kumar N, Vyas A, Agnihotri SK, Chattopadhyay N, Sachdev M. Small secretory proteins of immune cells can modulate gynecological cancers. Semin Cancer Biol. 2022;86(Pt 3):513\u201331.","journal-title":"Semin Cancer Biol"},{"issue":"4S","key":"2411_CR154","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jaci.2018.10.054","volume":"144","author":"A Dudeck","year":"2019","unstructured":"Dudeck A, Koberle M, Goldmann O, Meyer N, Dudeck J, Lemmens S, Rohde M, Roldan NG, Dietze-Schwonberg K, Orinska Z, Medina E, Hendrix S, Metz M, Zenclussen AC, von Stebut E, Biedermann T. Mast cells as protectors of health. J Allergy Clin Immunol. 2019;144(4S):S4\u201318.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2411_CR155","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tcb.2020.12.001","volume":"31","author":"M Kreileder","year":"2021","unstructured":"Kreileder M, Barrett I, Bendtsen C, Brennan D, Kolch W. Signaling dynamics regulating crosstalks between T-cell activation and immune checkpoints. Trends Cell Biol. 2021;31(3):224\u201335.","journal-title":"Trends Cell Biol"},{"key":"2411_CR156","doi-asserted-by":"publisher","first-page":"103409","DOI":"10.1016\/j.ebiom.2021.103409","volume":"68","author":"J Zhang","year":"2021","unstructured":"Zhang J, He T, Xue L, Guo H. Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine. 2021;68:103409.","journal-title":"EBioMedicine"},{"key":"2411_CR157","doi-asserted-by":"crossref","unstructured":"Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB, Matsuzaki J, Koya RC, Blom AM, McLeish KR, Qu J, Ram S, Moysich KB, Abrams SI, Odunsi K, Zsiros E, Segal BH. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight. 2019;4(5).","DOI":"10.1172\/jci.insight.122311"},{"issue":"3","key":"2411_CR158","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41573-024-01098-w","volume":"24","author":"S Viel","year":"2025","unstructured":"Viel S, Vivier E, Walzer T, Marcais A. Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer. Nat Rev Drug Discov. 2025;24(3):190\u2013208.","journal-title":"Nat Rev Drug Discov"},{"key":"2411_CR159","doi-asserted-by":"publisher","unstructured":"Galluzzi L, Smith KN, Liston A, Garg AD. The diversity of CD8(+) T cell dysfunction in cancer and viral infection. Nat Rev Immunol. 2025. https:\/\/doi.org\/10.1038\/s41577-025-01161-6. Online ahead of print.","DOI":"10.1038\/s41577-025-01161-6"},{"issue":"1","key":"2411_CR160","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","volume":"25","author":"D Hanahan","year":"2025","unstructured":"Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat Rev Cancer. 2025;25(1):41\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2411_CR161","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/cam4.3337","volume":"10","author":"TR McCaw","year":"2021","unstructured":"McCaw TR, Goel N, Brooke DJ, Katre AA, Londo\u00f1o AI, Smith HJ, Randall TD, Arend RC. Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. Cancer Med. 2021;10(2):709\u201317.","journal-title":"Cancer Med"},{"key":"2411_CR162","doi-asserted-by":"publisher","first-page":"738958","DOI":"10.3389\/fimmu.2021.738958","volume":"12","author":"PT Le","year":"2021","unstructured":"Le PT, Ha N, Tran NK, Newman AG, Esselen KM, Dalrymple JL, Schmelz EM, Bhandoola A, Xue HH, Singh PB, Thai TH. Targeting Cbx3\/HP1\u03b3 induces LEF-1 and IL-21R to promote tumor-infiltrating CD8 T-cell persistence. Front Immunol. 2021;12:738958.","journal-title":"Front Immunol"},{"issue":"9","key":"2411_CR163","doi-asserted-by":"publisher","first-page":"e1416","DOI":"10.1002\/ctm2.1416","volume":"13","author":"Y Gao","year":"2023","unstructured":"Gao Y, Shi H, Zhao H, Yao M, He Y, Jiang M, Li J, Li Z, Su S, Liu T, Yin C, Liao X, Yue W. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer. Clin Transl Med. 2023;13(9):e1416.","journal-title":"Clin Transl Med"},{"key":"2411_CR164","doi-asserted-by":"crossref","unstructured":"Wang C, He L, Peng J, Lu C, Zhang M, Qi X, Zhang M, Wang Y. Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy. J Immunother Cancer. 2024;12(8).","DOI":"10.1136\/jitc-2024-009404"},{"issue":"76","key":"2411_CR165","doi-asserted-by":"publisher","first-page":"eabk0957","DOI":"10.1126\/sciimmunol.abk0957","volume":"7","author":"K Itahashi","year":"2022","unstructured":"Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin YT, Watanabe S, Goto Y, Suzuki J, Aokage K, Tsuboi M, Minami Y, Ishii G, Ohe Y, Ise W, Kurosaki T, Suzuki Y, Koyama S, Nishikawa H. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022;7(76):eabk0957.","journal-title":"Sci Immunol"},{"key":"2411_CR166","doi-asserted-by":"crossref","unstructured":"Watts TH, Yeung KKM, Yu T, Lee S, Eshraghisamani R. TNF\/TNFR superfamily members in costimulation of T cell responses-revisited. Annu Rev Immunol. 2025;43(1):113\u201342.","DOI":"10.1146\/annurev-immunol-082423-040557"},{"issue":"11","key":"2411_CR167","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41423-024-01224-z","volume":"21","author":"Y Tang","year":"2024","unstructured":"Tang Y, Chen Z, Zuo Q, Kang Y. Regulation of CD8\u2009+\u2009T cells by lipid metabolism in cancer progression. Cell Mol Immunol. 2024;21(11):1215\u201330.","journal-title":"Cell Mol Immunol"},{"issue":"103","key":"2411_CR168","doi-asserted-by":"publisher","first-page":"eadf4726","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar V, Dinter T, Spranger S. Architects of immunity: how dendritic cells shape CD8(+) T cell fate in cancer. Sci Immunol. 2025;10(103):eadf4726.","journal-title":"Sci Immunol"},{"issue":"19","key":"2411_CR169","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-19-0880","volume":"79","author":"J Trillo-Tinoco","year":"2019","unstructured":"Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido \u00c1, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, Ruffell B, Conejo-Garcia JR, Rodriguez PC. AMPK Alpha-1 intrinsically regulates the function and differentiation of tumor myeloid-derived suppressor cells. Cancer Res. 2019;79(19):5034\u201347.","journal-title":"Cancer Res"},{"issue":"8040","key":"2411_CR170","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41586-024-08071-y","volume":"635","author":"SM Hwang","year":"2024","unstructured":"Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Marin Falco M, Salvagno C, Emmanuelli A, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Yu X, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, V\u00e4h\u00e4rautio A, Song M, Cubillos-Ruiz JR. Transgelin 2 guards T cell lipid metabolism and antitumour function. Nature. 2024;635(8040):1010\u20138.","journal-title":"Nature"},{"issue":"14","key":"2411_CR171","doi-asserted-by":"publisher","first-page":"e2104452","DOI":"10.1002\/advs.202104452","volume":"9","author":"P Gupta","year":"2022","unstructured":"Gupta P, Kadamberi IP, Mittal S, Tsaih SW, George J, Kumar S, Vijayan DK, Geethadevi A, Parashar D, Topchyan P, McAlarnen L, Volkman BF, Cui W, Zhang KYJ, Di Vizio D, Chaluvally-Raghavan P, Pradeep S. Tumor derived extracellular vesicles drive T cell exhaustion in tumor microenvironment through sphingosine mediated signaling and impacting immunotherapy outcomes in ovarian cancer. Adv Sci (Weinh). 2022;9(14):e2104452.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2411_CR172","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13046-023-02798-8","volume":"42","author":"A Hrvat","year":"2023","unstructured":"Hrvat A, Schmidt M, Wagner B, Zwanziger D, Kimmig R, Volbracht L, Brandau S, Mallmann-Gottschalk N. Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites. J Exp Clin Cancer Res. 2023;42(1):235.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2411_CR173","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12964-024-01834-0","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Wu M, Yang Y, Mei X, Wang L, Wang J, Wang Z, He S, Liu H, Jiang H, Qu S, Zhang Y, Chen Y, Tian X, Huang Y, Wang H. BTN3A1 expressed in cervical cancer cells promotes V\u03b39V\u03b42 T cells exhaustion through upregulating transcription factors NR4A2\/3 downstream of TCR signaling. Cell Commun Signal. 2024;22(1):459.","journal-title":"Cell Commun Signal"},{"key":"2411_CR174","doi-asserted-by":"crossref","unstructured":"Balan\u00e7a CC, Salvioni A, Scarlata CM, Michelas M, Martinez-Gomez C, Gomez-Roca C, Sarradin V, Tosolini M, Valle C, Pont F, Ferron G, Gladieff L, Vergez S, Dupret-Bories A, Mery E, Rochaix P, Fourni\u00e9 JJ, Delord JP, Devaud C, Martinez A, Ayyoub M. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39\u2009+\u2009CD4 T cells. JCI Insight. 2021;6(2).","DOI":"10.1172\/jci.insight.142513"},{"issue":"11","key":"2411_CR175","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M, Kyi C, O\u2019Cearbhaill RE, Liu C, Dao T, Scheinberg DA. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023;72(11):3773\u201386.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2411_CR176","doi-asserted-by":"publisher","first-page":"e2013201","DOI":"10.1001\/jamanetworkopen.2020.13201","volume":"3","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han X, Shi Y. Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors. JAMA Netw Open. 2020;3(8):e2013201.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2411_CR177","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","volume":"25","author":"N Chuangchot","year":"2023","unstructured":"Chuangchot N, Jamjuntra P, Yangngam S, Luangwattananun P, Thongchot S, Junking M, Thuwajit P, Yenchitsomanus PT, Thuwajit C. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways. Breast Cancer Res. 2023;25(1):86.","journal-title":"Breast Cancer Res"},{"key":"2411_CR178","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.omto.2021.02.013","volume":"20","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu G, Liu J, Yang M, Fu J, Liu G, Li D, Gu Z, Zhang L, Pan Y, Cui X, Wang L, Zhang L, Tian X. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. Mol Ther Oncolytics. 2021;20:556\u201368.","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"2411_CR179","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1078-0432.CCR-24-2469","volume":"31","author":"A Monette","year":"2025","unstructured":"Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater HA, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. The society for immunotherapy of cancer perspective on tissue-based technologies for immuno-oncology biomarker discovery and application. Clin Cancer Res. 2025;31(3):439\u201356.","journal-title":"Clin Cancer Res"},{"issue":"51","key":"2411_CR180","doi-asserted-by":"publisher","first-page":"56712","DOI":"10.1021\/acsami.0c15239","volume":"12","author":"Z Luo","year":"2020","unstructured":"Luo Z, Liu Z, Liang Z, Pan J, Xu J, Dong J, Bai Y, Deng H, Wei S. Injectable porous microchips with oxygen reservoirs and an immune-niche enhance the efficacy of CAR T cell therapy in solid tumors. ACS Appl Mater Interfaces. 2020;12(51):56712\u201322.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"2411_CR181","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ymthe.2019.11.028","volume":"28","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ. Jr., CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies. Mol Ther. 2020;28(2):548\u201360.","journal-title":"Mol Ther"},{"issue":"2","key":"2411_CR182","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","volume":"5","author":"A Ghasemi","year":"2024","unstructured":"Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, Fournier N, Torchia B, Martinez Bedoya D, Davanture S, Fernandez-Vaquero M, Fan C, Janzen J, Mohammadzadeh Y, Genolet R, Mansouri N, Wenes M, Migliorini D, Heikenwalder M, De Palma M. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat Cancer. 2024;5(2):240\u201361.","journal-title":"Nat Cancer"},{"issue":"3","key":"2411_CR183","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, Savoldo B. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol Ther. 2017;25(3):580\u201392.","journal-title":"Mol Ther"},{"key":"2411_CR184","doi-asserted-by":"crossref","unstructured":"Ventin M, Cattaneo G, Arya S, Jia J, Gelmi MC, Sun Y, Maggs L, Ksander BR, Verdijk RM, Boland GM, Jenkins RW, Haq R, Jager MJ, Wang X, Ryeom S, Ferrone CR. Chimeric antigen receptor T cell with an inducible caspase 9 suicide gene eradicates uveal melanoma liver metastases via B7-H3 targeting. Clin Cancer Res. 2024;30(15):3243\u201358.","DOI":"10.1158\/1078-0432.CCR-24-0071"},{"issue":"1","key":"2411_CR185","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561.","journal-title":"Oncoimmunology"},{"issue":"38","key":"2411_CR186","doi-asserted-by":"publisher","first-page":"10666","DOI":"10.1073\/pnas.1611481113","volume":"113","author":"XF Liu","year":"2016","unstructured":"Liu XF, Xiang L, Zhou Q, Carralot JP, Prunotto M, Niederfellner G, Pastan I. Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. Proc Natl Acad Sci U S A. 2016;113(38):10666\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2411_CR187","doi-asserted-by":"crossref","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35(3):473\u2013488 e6.","DOI":"10.1016\/j.ccell.2019.02.006"},{"key":"2411_CR188","doi-asserted-by":"crossref","unstructured":"Jin BY, Campbell TE, Draper LM, Stevanovic S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3(8).","DOI":"10.1172\/jci.insight.99488"},{"issue":"12","key":"2411_CR189","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ccell.2021.10.011","volume":"39","author":"F Uhlitz","year":"2021","unstructured":"Uhlitz F, Zamarin D. Rejuvenating dysfunctional T cells in ovarian cancer: CD28 is the license to kill. Cancer Cell. 2021;39(12):1567\u20139.","journal-title":"Cancer Cell"},{"key":"2411_CR190","doi-asserted-by":"crossref","unstructured":"O\u2019Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW, Hegg B, Ortuzar Feliu W, Ancukiewicz M, Lugowska I. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022;40(7):762\u2013771.","DOI":"10.1200\/JCO.21.02067"},{"issue":"9","key":"2411_CR191","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.trecan.2019.06.004","volume":"5","author":"EK Lee","year":"2019","unstructured":"Lee EK, Konstantinopoulos PA. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer. 2019;5(9):524\u20138.","journal-title":"Trends Cancer"},{"issue":"24","key":"2411_CR192","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1158\/1078-0432.CCR-24-0606","volume":"30","author":"YK Chae","year":"2024","unstructured":"Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. SWOG\/NCI phase II dual anti-CTLA-4\/PD-1 blockade in rare tumors: nonepithelial ovarian cancer. Clin Cancer Res. 2024;30(24):5593\u2013600.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2411_CR193","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s40425-019-0742-6","volume":"7","author":"F Baettig","year":"2019","unstructured":"Baettig F, Vlajnic T, Vetter M, Glatz K, Hench J, Frank S, Bihl M, Lopez R, Dobbie M, Heinzelmann-Schwarz V, Montavon C. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. J Immunother Cancer. 2019;7(1):281.","journal-title":"J Immunother Cancer"},{"key":"2411_CR194","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jconrel.2021.05.034","volume":"335","author":"C Xia","year":"2021","unstructured":"Xia C, Li M, Ran G, Wang X, Lu Z, Li T, Tang X, Zhang Z, He Q. Redox-responsive nanoassembly restrained myeloid-derived suppressor cells recruitment through autophagy-involved lactate dehydrogenase A silencing for enhanced cancer immunochemotherapy. J Control Release. 2021;335:557\u201374.","journal-title":"J Control Release"},{"issue":"1","key":"2411_CR195","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","volume":"9","author":"R Fu","year":"2024","unstructured":"Fu R, Qi R, Xiong H, Lei X, Jiang Y, He J, Chen F, Zhang L, Qiu D, Chen Y, Nie M, Guo X, Zhu Y, Zhang J, Yue M, Cao J, Wang G, Que Y, Fang M, Wang Y, Chen Y, Cheng T, Ge S, Zhang J, Yuan Q, Zhang T, Xia N. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct Target Ther. 2024;9(1):118.","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"2411_CR196","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, Saatcioglu F. Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management. Theranostics. 2024;14(18):6913\u201334.","journal-title":"Theranostics"},{"issue":"2","key":"2411_CR197","doi-asserted-by":"publisher","first-page":"e2406328","DOI":"10.1002\/advs.202406328","volume":"12","author":"Q Chen","year":"2025","unstructured":"Chen Q, Li Y, Hu J, Xu Z, Wang S, Cai N, He M, Xiao Y, Ding Y, Sun M, Li C, Cao Y, Wang Z, Zhou F, Wang G, Wang C, Tu J, Hu H, Sun C. Local exosome inhibition potentiates mild photothermal immunotherapy against breast cancer. Adv Sci (Weinh). 2025;12(2):e2406328.","journal-title":"Adv Sci (Weinh)"},{"key":"2411_CR198","doi-asserted-by":"crossref","unstructured":"Emens LA, Moussion C, Hwu P, Gulley JL, Ohashi PS, Bifulco CB, Feltquate D. SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development. J Immunother Cancer. 2025;13(6).","DOI":"10.1136\/jitc-2024-010739"},{"issue":"1","key":"2411_CR199","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/2326-6066.CIR-19-0315","volume":"8","author":"G Galliverti","year":"2020","unstructured":"Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W, Korman AJ, Coussens LM, Swartz MA, Hanahan D. Myeloid cells orchestrate systemic immunosuppression, impairing the efficacy of immunotherapy against HPV(+) cancers. Cancer Immunol Res. 2020;8(1):131\u201345.","journal-title":"Cancer Immunol Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02411-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:26:39Z","timestamp":1757309199000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02411-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2411"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02411-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}